AUROPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | AUROPHARMA | Market Cap | 83,238 Cr. | Current Price | 1,436 ₹ | High / Low | 1,550 ₹ |
| Stock P/E | 34.3 | Book Value | 391 ₹ | Dividend Yield | 0.28 % | ROCE | 13.0 % |
| ROE | 11.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,400 ₹ | DMA 200 | 1,262 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 692 Cr. | PAT Prev Qtr | 595 Cr. |
| RSI | 47.2 | MACD | 23.3 | Volume | 8,15,463 | Avg Vol 1Wk | 17,56,070 |
| Low price | 1,016 ₹ | High price | 1,550 ₹ | PEG Ratio | 1.32 | Debt to equity | 0.19 |
| 52w Index | 78.6 % | Qtr Profit Var | 69.6 % | EPS | 41.6 ₹ | Industry PE | 31.6 |
- 📈 Chart Patterns: AUROPHARMA is trading at 1,436 ₹, showing recovery momentum after recent highs of 1,550 ₹. Support lies around 1,400–1,410 ₹, resistance near 1,480–1,500 ₹. Trendlines suggest sideways consolidation with bullish undertone.
- 📊 Moving Averages: Price is above both 50 DMA (1,400 ₹) and 200 DMA (1,262 ₹), confirming medium-term strength.
- 📉 RSI: At 47.2, RSI is neutral, indicating balanced momentum without overbought/oversold signals.
- 📈 MACD: Positive (23.3), showing bullish divergence and short-term upward bias.
- 📊 Bollinger Bands: Price is near the mid-band, suggesting consolidation with potential breakout if volumes improve.
- 📊 Volume Trends: Current volume (8,15,463) is below weekly average (17,56,070), showing reduced participation despite price strength.
- 📌 Momentum Signals: Entry zone around 1,400–1,410 ₹; exit zone near 1,480–1,500 ₹.
- 🔄 Trend Status: Consolidating with bullish bias.
Positive
- PAT growth (+69.6%, 692 Cr. vs 595 Cr.) shows strong earnings momentum.
- EPS of 41.6 ₹ provides solid earnings base.
- Price above both 50 DMA and 200 DMA confirms bullish structure.
- FII holdings increased (+1.29%), showing foreign investor confidence.
Limitation
- RSI neutral, limiting immediate upside momentum.
- DII holdings decreased (-1.84%), showing domestic investor caution.
- P/E (34.3) slightly above industry average (31.6), suggesting premium valuation.
- Volume below average, reducing conviction in breakout potential.
Company Negative News
- Valuation stretched compared to peers.
- Decline in DII holdings signals reduced domestic confidence.
Company Positive News
- Quarterly profits surged significantly.
- FII inflows support momentum.
- Technical strength above DMA levels.
Industry
- Industry P/E at 31.6 highlights sector trading at lower multiples.
- Pharma sector remains resilient with steady demand outlook.
Conclusion
AUROPHARMA is consolidating with bullish bias supported by strong quarterly earnings and positive MACD. Entry near 1,400–1,410 ₹ offers favorable risk-reward, with exit around 1,480–1,500 ₹. Valuation remains slightly stretched and volumes are below average, so momentum trades should be managed with strict stop-loss discipline.
Would you like me to expand this into a sector overlay benchmarking against pharma peers, or refine it into a swing trade outlook with medium-term targets?